Literature DB >> 19242372

CpG-C oligodeoxynucleotides limit the deleterious effects of beta-adrenoceptor stimulation on NK cytotoxicity and metastatic dissemination.

Yael Goldfarb1, Marganit Benish, Ella Rosenne, Rivka Melamed, Ben Levi, Ariella Glasner, Shamgar Ben-Eliyahu.   

Abstract

Suppression of natural killer (NK) cell activity is common after stress, has been reported to predict malignant recurrence in cancer patients, and was shown to underlie metastatic dissemination in animal models. We have previously reported that catecholamines play a major role in NK cell suppression, particularly in the context of physiologic stress and surgery. In the current study using Fisher 344 rats, we examined the prophylactic use of different regimens of type-C CpG oligodeoxynucleotides (CpG-C ODN) on NK activity and metastatic dissemination in the context of pharmacologic stress (using metaproterenol for beta-adrenoceptor stimulation). Our results indicated that the beneficial effects of CpG-C ODN were more profound under pharmacologic stress than under baseline conditions. A bolus of CpG-C ODN (330 microg/kg, intraperitoneally) 24 hours before metaproterenol-challenge was most effective at reducing lung tumor retention of an experimental syngeneic mammary adenocarcinoma (MADB106), although having no observable side effects. Depletion of NK cells revealed their key role in improving baseline levels of resistance to metastatic dissemination after CpG-C ODN administration. When NK cell cytotoxicity was assessed in the circulation and the marginating-pulmonary immune compartments, we found that CpG-C ODN protected individual NK cells from metaproterenol-induced suppression in both compartments. Moreover, in the critical marginating-pulmonary compartment, CpG-C ODN also elevated baseline cytotoxicity per NK cell against MADB106 tumor cells, and increased NK cell numbers in nonstressed rats. Overall, prophylactic CpG-C ODN treatment can improve immunocompetence and potentially reduce metastatic dissemination, especially in clinical settings characterized by enhanced sympathetic stress responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19242372      PMCID: PMC2738855          DOI: 10.1097/CJI.0b013e31819a2982

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  52 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status.

Authors:  J L Mccoy; R Rucker; J A Petros
Journal:  Breast Cancer Res Treat       Date:  2000-04       Impact factor: 4.872

Review 3.  Beta-adrenergic receptors in human leukocyte subpopulations.

Authors:  R Landmann
Journal:  Eur J Clin Invest       Date:  1992-10       Impact factor: 4.686

4.  Lytic units reconsidered: pitfalls in calculation and usage.

Authors:  R E Pollock; S O Zimmerman; P Fuchshuber; E Lotzová
Journal:  J Clin Lab Anal       Date:  1990       Impact factor: 2.352

5.  Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.

Authors:  A F Carpentier; L Chen; F Maltonti; J Y Delattre
Journal:  Cancer Res       Date:  1999-11-01       Impact factor: 12.701

Review 6.  The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system.

Authors:  I J Elenkov; R L Wilder; G P Chrousos; E S Vizi
Journal:  Pharmacol Rev       Date:  2000-12       Impact factor: 25.468

7.  Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors.

Authors:  S Ben-Eliyahu; G Shakhar; G G Page; V Stefanski; K Shakhar
Journal:  Neuroimmunomodulation       Date:  2000       Impact factor: 2.492

8.  Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis.

Authors:  Marganit Benish; Inbal Bartal; Yael Goldfarb; Ben Levi; Roi Avraham; Amiram Raz; Shamgar Ben-Eliyahu
Journal:  Ann Surg Oncol       Date:  2008-04-09       Impact factor: 5.344

9.  Deoxynucleic acids from Cryptococcus neoformans activate myeloid dendritic cells via a TLR9-dependent pathway.

Authors:  Kiwamu Nakamura; Akiko Miyazato; Gang Xiao; Masumitsu Hatta; Ken Inden; Tetsuji Aoyagi; Kohei Shiratori; Kiyoshi Takeda; Shizuo Akira; Shinobu Saijo; Yoichiro Iwakura; Yoshiyuki Adachi; Naohito Ohno; Kazuo Suzuki; Jiro Fujita; Mitsuo Kaku; Kazuyoshi Kawakami
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

10.  Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells.

Authors:  W H Chambers; N L Vujanovic; A B DeLeo; M W Olszowy; R B Herberman; J C Hiserodt
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

View more
  18 in total

1.  Continuous stress disrupts immunostimulatory effects of IL-12.

Authors:  Ben Levi; Marganit Benish; Yael Goldfarb; Liat Sorski; Rivka Melamed; Ella Rosenne; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2011-01-28       Impact factor: 7.217

2.  Stress and skin leukocyte trafficking as a dual-stage process.

Authors:  Elad Neeman; Lee Shaashua; Marganit Benish; Gayle G Page; Oded Zmora; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2011-09-19       Impact factor: 7.217

3.  In vivo suppression of NK cell cytotoxicity by stress and surgery: glucocorticoids have a minor role compared to catecholamines and prostaglandins.

Authors:  Ella Rosenne; Liat Sorski; Lee Shaashua; Elad Neeman; Pini Matzner; Ben Levi; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2013-12-12       Impact factor: 7.217

Review 4.  Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement.

Authors:  Elad Neeman; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2012-04-04       Impact factor: 7.217

5.  CpG-C immunotherapeutic efficacy is jeopardized by ongoing exposure to stress: potential implications for clinical use.

Authors:  Yael Goldfarb; Ben Levi; Liat Sorski; Dan Frenkel; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2010-07-23       Impact factor: 7.217

Review 6.  A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins.

Authors:  Elad Neeman; Oded Zmora; Shamgar Ben-Eliyahu
Journal:  Clin Cancer Res       Date:  2012-07-02       Impact factor: 12.531

Review 7.  Exploiting the critical perioperative period to improve long-term cancer outcomes.

Authors:  Maya Horowitz; Elad Neeman; Eran Sharon; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2015-01-20       Impact factor: 66.675

8.  PGE2 suppresses NK activity in vivo directly and through adrenal hormones: effects that cannot be reflected by ex vivo assessment of NK cytotoxicity.

Authors:  G Meron; Y Tishler; L Shaashua; E Rosenne; B Levi; R Melamed; N Gotlieb; P Matzner; L Sorski; S Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2012-11-12       Impact factor: 7.217

9.  Stress impairs the efficacy of immune stimulation by CpG-C: Potential neuroendocrine mediating mechanisms and significance to tumor metastasis and the perioperative period.

Authors:  B Levi; P Matzner; Y Goldfarb; L Sorski; L Shaashua; R Melamed; E Rosenne; G G Page; S Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2016-03-02       Impact factor: 7.217

10.  Perioperative treatment with the new synthetic TLR-4 agonist GLA-SE reduces cancer metastasis without adverse effects.

Authors:  Pini Matzner; Liat Sorski; Lee Shaashua; Ely Elbaz; Hagar Lavon; Rivka Melamed; Ella Rosenne; Neta Gotlieb; Amit Benbenishty; Steve G Reed; Shamgar Ben-Eliyahu
Journal:  Int J Cancer       Date:  2015-10-26       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.